Browsing Tag
Dr. Reddy’s Laboratories Limited
6 posts
Dr. Reddy’s lands Qdenga distribution deal as India prepares first dengue vaccine launch
Dr. Reddy’s Laboratories will promote and distribute Takeda’s Qdenga dengue vaccine in India, creating a new commercial opportunity after regulators approved the country’s first dengue vaccine for people aged four to 60.
Immutep shares surge 27% as efti strategy narrows after TACTI-004 failure
Immutep Limited is narrowing eftilagimod alfa development to two oncology settings and returning to 200-litre manufacturing after finding structural differences between the material used in failed Phase III TACTI-004 and earlier successful studies.
Aspen Pharmacare (JSE: APN) ends FY26 with net cash after R28bn APAC sale
Aspen expects continuing-operations normalised earnings per share to rise 19%-24% after a sharp second-half recovery, while the APAC disposal transformed its balance sheet.
Who is really leading Indian pharma in 2026? The top 10 companies explained beyond the hype
Discover the top 10 pharma companies in India in 2026, who leads by revenue, reach, and strategy, and why the ranking is more complex than it looks.
Dr. Reddy’s (NSE: DRREDDY) acquires Progynova and Cyclo-Progynova to enter India’s hormone replacement therapy market
Dr. Reddy’s Laboratories Limited enters hormone replacement therapy with a $32 million India acquisition. Find out why this move matters now.
Biologics race in Indian pharma: Can Glenmark’s AbbVie tie-up spark a broader innovation moment?
India’s biologics race heats up as Glenmark, Biocon, Sun Pharma, Dr. Reddy’s, and Lupin push beyond generics—see how each strategy stacks up.